Alvogen Pumping $250M into Developing Biosimilars, with New Iceland Plant

Company plans to produce its own biosimilars, the first of which are already in the advanced development stage.

Teva Parts Ways with CureTech, Takes $109M Hit

Companies sought to commercialize mAb CTT-011 since 2006.

Antibody Discovery Looks Over the Horizon

Antibody discovery platforms have come a long way since the initial steps toward understanding what antibodies do and how to harness them. GEN recently spoke...

Genzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial

Firm says positive data from CARE-II means U.S. and EU filings for Lemtrada are on track for Q1 2012.

Abbott and Seattle Expand ADC Collaboration

Abbott is paying Seattle Genetics $25 million to expand the firms’ existing antibody-drug conjugate (ADC) alliance. The new deal gives Abbott access to Seattle’s auristatin-based ADC technology for use with antibodies against additional targets.

NewLink Wins $20M from Merck & Co. for Ebola Vaccine Trial...

Phase II/III study will assess 27,000 adults for response to placebo or any of two Ebola vaccine candidates—the partners' rVSV-EBOV, and GSK's cAd3-EBOZ.

Genmab Partners on Cancer Antibodies with BliNK Biomedical, Launches $503M U.S....

Genmab wrapped up an eventful week on Friday as the Danish biotech launched an up to $200 million-per-product cancer therapy collaboration with BliNK Biomedical, and raised $503 million through an American initial public offering (IPO).

Fight-or-Flight Time? That’s When Calcium Channels Give Up Rad

The role of adrenaline in triggering the fight-or-flight response is one of the most well-studied phenomena in biology. However, the precise molecular mechanisms for how the hormone stimulates cardiac function have remained unclear. Now a proteomic proximity study had revealed that a protein called Rad dampens the activity of calcium channels.

PPD Inks Deal with HIHT University to Increase Network in Northern...

Company will provide infrastructure support and training.

Tool and Service Providers

Biotechnology tool and service companies will continue struggling with reduced demand from the academic segment of their customers and portions of the industry, if a check of third-quarter results is any indication. Details on how this could play out can be read here. Those that are performing well despite the downturn have a portfolio that spans instrumentation, consumables, and services. Last month, Frost & Sullivan issued a report concluding that the global contract research organization market resumed its growth trajectory last year and is expected to grow at a compound annual growth rate of 10.5% until 2017. For vendors dependent on installation of new systems as a primary source of revenue, things don’t look so rosy. Do you think consolidation will be the answer to such companies’ prayers?

Recently Featured

Scroll Up